Industry landscapes
The companies, capital and talent shaping clinical trials technology in the United States. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
102 of 1,116 tracked companies have open roles.
272 of 1,116 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 413 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 38.0% of disclosed capital, while 75.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $251.08M | 54 | 34 |
| 2017 | $1.05B | 66 | 28 |
| 2018 | $414.71M | 57 | 37 |
| 2019 | $1.72B | 56 | 41 |
| 2020 | $1.65B | 60 | 42 |
| 2021 | $1.85B | 46 | 41 |
| 2022 | $1.61B | 37 | 42 |
| 2023 | $720.56M | 46 | 39 |
| 2024 | $325.99M | 21 | 26 |
| 2025 | $371.06M | 13 | 26 |
Share of all disclosed company funding.
494 recorded rounds since 2016
Recorded participation in clinical trials technology company rounds since 2016.
Backed by Avenue Capital Group and Broadoak Capital Partners.
Backed by Jetstream Venture Fund.
Backed by Series X Capital and Alphabet and others.
Backed by Insight Partners and Felicis Ventures and others.
Backed by DOMiNO Ventures and Curiosity.
Backed by ARCHIMED.
Backed by Blackstone and Tiger Global Management and others.
Backed by Series X Capital and Alphabet and others.
Backed by Goldman Sachs Investment Partners.
Backed by Altimeter Capital and Coatue and others.
Backed by Sierra Ventures and Coatue and others.
Backed by Arch Venture Partners and General Catalyst and others.
Backed by Google and Novo Holdings and others.
Backed by New Enterprise Associates and Novo Holdings and others.
Backed by McKesson and B Capital and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2022 · company accounts; aggregate reporting threshold not met · 1 reporting entities from 4 eligible matches.
Sum of reporting-entity revenue; not the United States market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 1 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2022 · 1 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Science 37 ↗1819113 | $70.1m | $-51.0m | -72.7% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the the United States companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
10 of the 1,116 companies on this page carry a measured traffic record (0.9%); these are the largest of those, by monthly visits. The median among them is 319,990 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Apex Focus Groupapexfocusgroup.com | 7,193,132 | 27 | 96.4% |
| IQVIAiqvia.com | 1,088,743 | 51 | 43.3% |
| ClinicalConnectionclinicalconnection.com | 965,219 | 30 | 99% |
| AutoCruitmentautocruitment.com | 456,440 | 26 | 98.4% |
| Luminate Healthluminatehealth.com | 444,879 | 24 | 66% |
| StudyKikstudykik.com | 195,101 | 25 | 98.5% |
| Nucleus Networknucleusnetwork.com | 185,966 | 39 | 87.5% |
| Limsabc.comlimsabc.com | 175,976 | 12 | 0% |
| TrialXtrialx.com | 138,961 | 32 | 86.7% |
| Leapcureleapcure.com | 47,342 | 27 | 93.3% |
Visits and authority are third-party web estimates, not company-reported figures.
66 of these companies (5.9%) publish at least one Android app — 352 apps in all, carrying 3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Evidation: Earn Health RewardsEvidation | 1.5M | 4.2 | Health & Fitness |
| eAuditor Audits & InspectionsLyons Information Systems | 421.2K | 4.2 | Productivity |
| TrialMax AppSignant Health | 166.3K | 4.2 | Tools |
| Verily MeVerily | 113.3K | 4.4 | Medical |
| IQVIA Study HubIQVIA | 105.4K | 3.9 | Health & Fitness |
| My ClinCard®Greenphire | 99K | 2.7 | Finance |
| Sales ViewIQVIA | 94.4K | — | Business |
| IQVIA ScribeAltavoz | 42.6K | 2.7 | Medical |
| RealLife ExpLifeData | 38.3K | 3.5 | Medical |
| i-BelongBelong | 38.3K | 4.1 | Social |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 173 | 2.9M | Evidation: Earn Health Rewards 1.5M | |
| Healthcare It | 50 | 876.9K | eAuditor Audits & Inspections 421.2K | |
| Clinical Labs It | 17 | 431.9K | Quartzy 5.1K | |
| Grc Software | 2 | 421.9K | QMS Audit Pro 643 | |
| Big Data Analytics | 16 | 330.2K | Verily Me 113.3K | |
| Social Platforms | 3 | 86.6K | i-Belong 38.3K | |
| Biopharma Outsourcing | 180 | 29.5K | MyTrialApp 5.1K | |
| Artificial Intelligence | 3 | 23.6K | Viz.ai 18.5K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 336 of 352 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
75 companies hiring · $9.89B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Signant Health has acquired Ametris, a wearable digital health systems manufacturer, in a tech M&A deal.
Quartzy, a vertically integrated procurement platform for the life sciences industry, announced it has secured $23 million in financing from Avenue Capital Group and BroadOak Capital Partners.
Last April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson’s Research.
First, he is simultaneously leading negotiations for multiple major mining assets, including ERG and Kazzinc—where, under the Glencore financing arrangement, he is expected to pursue the purchase of a 70% stake.
Condor Software has now raised a total of $29.5M in total equity funding and is backed by 645 Ventures, Bramalea Partners, Felicis, Insight Partners, Pamir Ventures, Prebys Ventures, and SNR.vc.
Homburger advised the shareholders of Swiss-based Clariness on the sale of 100% of their shares to SubjectWell.
Antidote, an AI-powered billing compliance platform for law firms, announced today it has raised $5 million in seed funding led by Lakestar, with participation from Concept Ventures, The LegalTech Fund, and several unnamed industry angels.
Title21 Health Solutions acquired MyCellHub, a life sciences software provider, to enhance its digital health and laboratory management offerings.
In an anticipated move, Dassault Systèmes, a French enterprise IT firm (its better-known aviation business is a separate company) will acquire Medidata Solutions, at a 17% premium over the stock price it had before rumors began circulating this spring.
Back in April, in an effort to support clinical trial sponsor’s trial designs with direct-to-patient and home healthcare provider capabilities, Myonex also acquired SaveWay Compounding Pharmacy.
Top 10 categories among 170 recorded events in the 24-month window.
2 companies with recorded IPO activity
IPO · Nasdaq Global Market1 reports
IPO · Hong Kong Stock Exchange1 reports
27 tracked people moves
Appointment Chief Transformation and AI Officer
Appointment Chief Operating Officer
Appointment Chief Revenue Officer
Appointment Chief Regulatory Officer
Appointment VP of Marketing
Appointment Executive Vice President of Sales and Commercial Strategy
Appointment Chief People Officer
Retirement Previously Chief Executive Officer
Products, platforms and features in the recorded window
AI analytics and automation platform
Health App
Clinical Health Solution version 5.06
6 recorded customer wins
Customer: MP BiomedicalsLife sciences
Customer: biotiumLife sciences
Customer: stmicroelectronicsEnergy
Customer: University of Pittsburgh Medical CenterHealthcare
Customer: novo nordiskHealthcare
2 companies with reported reductions
Scale not stated rolesstrategic restructuring
Scale not stated rolescost reduction
1 recorded events
continued listing grantedNasdaq
1 tracked suits
breach of representations and warranties in merger agreementCivil ·
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Signant Health→Ametris | Announced | 2026-04-20 | Not stated in snapshot |
| Shakhmurat Mutalip→ERG ↗ | Rumored | 2026-03-23 | Not stated in snapshot |
| SubjectWell→clariness | Announced | 2026-02-11 | Not stated in snapshot |
| Suvoda→Greenphire ↗ | Completed | 2026-01-12 | Not stated in snapshot |
| Title21 Health Solutions→mycellhub | Announced | 2026-01-07 | Not stated in snapshot |
| Science 37→LifeSci Acquisition | Completed | 2026-01-01 | $235.0M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
3,713 postings in the preceding 12 months. The full 4,920-posting snapshot covers 109 employers.
155 tracked postings mention remote work.
1,539 postings specify a level.
Top skills across 4,920 tracked postings in the available jobs snapshot.
Median across 414 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Employees |
|---|---|
| Private Access ↗ | 1,060 |
| Care Access ↗ | 900 |
| SCC Soft Computer ↗ | 543 |
| Medable ↗ | 376 |
| OneStudyTeam ↗ | 309 |
| Javara Research ↗ | 233 |
| Castor ↗ | 230 |
| Saama ↗ | 213 |
592 founders and chief executives across 470 companies.
Granular Insurance, Google, ex-Co-Founder Chronicle, Symantec, Best Buy, Yahoo. University of Oregon BS 1998, San Francisco State University MBA 2006
Co-Founder Groupon, Lightbank, MediaBank, ex-Founder Echo Global Logistics. University of Michigan 1991, University of Michigan Law School JD 1994
The University of New Mexico
Care Access, ex-Signal Vine, ex-Rock Health, The Johns Hopkins University School of Medicine
Ex-CEO EDUSURG · UCL MBBS, Stanford University MBA 2016
Ex-The Activity Exchange, IMRSV, OneRiot, Ask.com, University of Iowa PhD 2014
Healthcare Foundry, Co-Founder Overstory Health, Daymark Health, Tulea Health, Playground Pediatrics…
Paradigm, ex-Stealth Startup, ex-Icon, Western Washington University, 1991
Brightinsight, ex-The Boston Consulting, ex-Flex, University of Chicago Pritzker school of medicine, 2003
Ex-WCG, Bioclinica.
Ex-CEO n2y, FairWarning, Bullhorn, Peoplenet. Georgia Institute of Technology 1994, Emory University - Goizueta Business School MAB 2004
Ex-Pubget, Microsoft, Commonwealth Capital, The Yankee Group. Dartmouth College AB, UC Berkeley Haas School of Business MBA 2007
103 profiles with education records.
19 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
2,388,337 articles in the measured 12-month window.
Clinical Trials Technology coverage across United States · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 512,406 |
| 2021Q3 | 529,666 |
| 2021Q4 | 501,080 |
| 2022Q1 | 548,984 |
| 2022Q2 | 543,513 |
| 2022Q3 | 553,318 |
| 2022Q4 | 618,575 |
| 2023Q1 | 649,627 |
| 2023Q2 | 647,579 |
| 2023Q3 | 585,192 |
| 2023Q4 | 554,702 |
| 2024Q1 | 578,668 |
| 2024Q2 | 562,408 |
| 2024Q3 | 560,605 |
| 2024Q4 | 586,951 |
| 2025Q1 | 878,734 |
| 2025Q2 | 597,875 |
| 2025Q3 | 1,348,181 |
| 2025Q4 | 324,679 |
| 2026Q1 | 460,115 |
| 2026Q2 | 255,362 |
Article volume measures coverage, not market sales.
219 recorded company events across 65 companies; percentages use that event total.
Clinical Trials Technology coverage across United States · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Clinical Trials Technology coverage across United States
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| investment deal | 6,461 | 2,680 | 141% |
| oil price volatility | 3,970 | 2,462 | 61% |
| private equity | 3,964 | 1,313 | 202% |
| countries | 3,925 | 1,959 | 100% |
| share price | 3,480 | 2,138 | 63% |
| etf trading | 2,759 | 1,278 | 116% |
| stock surge | 2,563 | 1,448 | 77% |
| investment | 2,521 | 721 | 250% |
| commodity trading | 2,495 | 1,336 | 87% |
| export sanctions | 2,426 | 928 | 161% |
| tariff negotiations | 13,814 | 23,129 | -40% |
| free trade deals | 5,758 | 9,226 | -38% |
| college playoffs | 784 | 5,771 | -86% |
| severe weather warning | 2,751 | 5,023 | -45% |
| economic slowdown | 2,353 | 4,478 | -47% |
Clinical Trials Technology coverage across United States
territories, disputed islands, tariff negotiations
44.8% critical · 20.8% positiveinvestment deal, inflation reports fx, currency intervention policies
45.9% critical · 41.3% positiveearnings report, stock performance, quarterly results
39.3% critical · 42.2% positiveClinical Trials Technology coverage across United States. Topic labels describe recorded classifications and can include broad context.
13,110 papers in the recorded india scope.
Tone counts: 12,011 positive · 703 neutral · 396 negative.
Landmark: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Landmark: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Landmark: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Common problems researchers identify · 0118.2% of this theme group
Researchers highlight challenges in moving metabolic biomarkers and disease diagnostics from discovery to clinical use.
Clinical trial (35) · MEDLINE (27) · Biomarker (29) · Disease (54)
Evolving Paradigms in Chronic Limb-threatening Ischemia: A Systematic Review of Current and Emerging Diagnostic and Therapeutic Approaches
A Practical Roadmap for Clinical Translation of Metabolic Biomarkers: A Review
| Year | Share index |
|---|---|
| 2022 | 865.9 |
| 2023 | 827.3 |
| 2024 | 831.6 |
| 2025 | 1262.9 |
Common problems researchers identify · 0217.5% of this theme group
Papers flag obstacles in tumor microenvironment and checkpoint pathways that limit current cancer immunotherapies.
Cancer (102) · Tumor microenvironment (30) · Breast cancer (25) · Immunotherapy (28)
Metabolic reprogramming and cancer progression
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
| Year | Share index |
|---|---|
| 2022 | 2422.1 |
| 2023 | 3082.5 |
| 2024 | 2613.2 |
| 2025 | 2334.4 |
Common problems researchers identify · 0317.1% of this theme group
Authors discuss inconsistencies and uncertainties in classifying and reporting gene variants for disease risk.
Gene (54) · Genome (47) · Gene expression (14) · Genetic testing (22)
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test result
Widespread Regulatory Turnover Across Human Segmental Duplications
| Year | Share index |
|---|---|
| 2022 | 2572.7 |
| 2023 | 2646.5 |
| 2024 | 2427.6 |
| 2025 | 1985.2 |
Common problems researchers identify · 0417.1% of this theme group
Works point to complex immune and metabolic pathways underlying neuro‑degenerative and cardiovascular disorders.
Disease (84) · Inflammation (26) · Pathogenesis (23) · Immune system (42)
Parkinson’s disease: etiopathogenesis and treatment
Immunometabolic Pathways in Cardiovascular Disease: Inflammation and Metabolic Dysfunction Beyond Traditional Risk Factors
| Year | Share index |
|---|---|
| 2022 | 3656.8 |
| 2023 | 3139.3 |
| 2024 | 3195.8 |
| 2025 | 3175.2 |
Common problems researchers identify · 0512.0% of this theme group
Studies note methodological gaps in metagenomics, epigenetics, and synthetic approaches for regenerative medicine.
Computational biology (45) · Synthetic biology (12) · Extracellular vesicles (12) · Regenerative medicine (10)
Clinical metagenomics
Epigenetics: Definition, Mechanisms and Clinical Perspective
| Year | Share index |
|---|---|
| 2022 | 1002.0 |
| 2023 | 1033.6 |
| 2024 | 1279.7 |
| 2025 | 938.0 |
Common problems researchers identify · 0611.3% of this theme group
Literature emphasizes unresolved inflammatory mechanisms connecting obesity, insulin resistance, and diabetes treatment.
Diabetes mellitus (45) · Disease (75) · Obesity (21) · Insulin resistance (14)
Inflammatory mechanisms linking obesity and metabolic disease
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
| Year | Share index |
|---|---|
| 2022 | 3247.1 |
| 2023 | 2770.6 |
| 2024 | 2817.3 |
| 2025 | 2753.4 |
Common problems researchers identify · 076.9% of this theme group
Authors raise concerns about variability and translational relevance of gut microbiome studies.
Microbiome (66) · Gut microbiome (17) · Human microbiome (14) · Gut flora (18)
Microbiota in health and diseases
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation
| Year | Share index |
|---|---|
| 2022 | 176.9 |
| 2023 | 161.2 |
| 2024 | 201.7 |
| 2025 | 230.8 |
Cautions · 0119.2% of this theme group
Cautions focus on uncertain efficacy of emerging immune checkpoints and genomic biomarkers in cancer therapy.
Cancer (26) · Breast cancer (16) · Transcriptome (10) · Tumor microenvironment (5)
[Strategic Combination Approaches in Cancer Immunotherapy].
Comparative analysis of potentially actionable genomic alterations in early-onset versus later-onset gastrointestinal cancers.
| Year | Share index |
|---|---|
| 2022 | 2765.3 |
| 2023 | 3333.3 |
| 2024 | 2910.0 |
| 2025 | 2686.7 |
Cautions · 0218.4% of this theme group
Papers advise restraint when interpreting early‑stage clinical data for nutraceuticals and novel lipid‑lowering agents.
Drug (17) · Drug discovery (8) · Clinical trial (15) · Disease (16)
The therapeutic potential of resveratrol: a review of clinical trials
Lipoprotein(a)-lowering therapies: a promising future
| Year | Share index |
|---|---|
| 2022 | 911.2 |
| 2023 | 888.9 |
| 2024 | 986.4 |
| 2025 | 1306.2 |
Cautions · 0317.0% of this theme group
Research warns about reproducibility and interpretation challenges for DNA methylation and protein‑structure biomarkers.
DNA methylation (7) · Antibody (6) · Protein structure (4) · Epigenetics (7)
Characterizing the Conformational Dynamics of an Intrinsically Disordered Localization Sequence
Epigenetic Markers of Response to Psychotherapy in Obsessive-Compulsive Disorder
| Year | Share index |
|---|---|
| 2022 | 444.9 |
| 2023 | 467.7 |
| 2024 | 361.0 |
| 2025 | 324.1 |
Cautions · 0414.1% of this theme group
Authors caution that plant‑focused genomic selection methods may not translate directly to human clinical contexts.
Gene (18) · Genetic testing (7) · Genome editing (6) · Genome (11)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2420.5 |
| 2023 | 2512.7 |
| 2024 | 2228.9 |
| 2025 | 1728.0 |
Cautions · 0513.9% of this theme group
Studies highlight inconsistent effects of SGLT2 inhibitors and insulin‑resistance metrics across patient subgroups.
Diabetes mellitus (12) · Type 2 diabetes (6) · Disease (15) · MEDLINE (11)
Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayes
Presenting non-insulin-based indices of insulin resistance relevant to pre-hypertension: A systematic review and meta-analysis
| Year | Share index |
|---|---|
| 2022 | 3201.5 |
| 2023 | 2723.9 |
| 2024 | 2771.9 |
| 2025 | 2711.7 |
Cautions · 0611.5% of this theme group
Works point out systematic biases in DNA sequencing pipelines and the need for more robust benchmarking.
DNA sequencing (16) · Genome (18) · Computational biology (13) · Benchmark (6)
Characterizing and measuring bias in sequence data
Critical Assessment of Metagenome Interpretation—a benchmark of metagenomics software
| Year | Share index |
|---|---|
| 2022 | 1389.5 |
| 2023 | 1365.3 |
| 2024 | 1669.5 |
| 2025 | 1346.5 |
Cautions · 075.9% of this theme group
Research stresses limited understanding of lasting antibiotic effects on gut flora and related disease risks.
Microbiome (15) · Gut flora (8) · Gut microbiome (5) · Metagenomics (5)
Long-term impacts of antibiotic exposure on the human intestinal microbiota
Human Gut Microbiome and Risk for Colorectal Cancer
| Year | Share index |
|---|---|
| 2022 | 221.0 |
| 2023 | 201.6 |
| 2024 | 252.5 |
| 2025 | 289.2 |
Opportunities · 0118.5% of this theme group
Opportunities focus on exploiting immune and metabolic pathways for new diabetes and cardiovascular treatments.
Disease (325) · Inflammation (102) · Diabetes mellitus (53) · Immune system (108)
Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities
Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 3678.0 |
| 2023 | 3167.0 |
| 2024 | 3229.4 |
| 2025 | 3203.8 |
Opportunities · 0217.3% of this theme group
Papers reveal how large‑scale gene association studies can pinpoint tissue‑specific disease drivers for drug discovery.
Genome (394) · Gene (264) · Genomics (118) · Genome-wide association study (67)
Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types
The druggable genome and support for target identification and validation in drug development
| Year | Share index |
|---|---|
| 2022 | 2539.2 |
| 2023 | 2616.9 |
| 2024 | 2403.6 |
| 2025 | 1960.3 |
Opportunities · 0315.8% of this theme group
Research showcases advanced bioinformatics workflows enabling integrated protein, nucleic‑acid, and microbiome analyses.
Proteomics (97) · Proteome (69) · Computational biology (104) · Workflow (58)
Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome \n
Large-scale multi-omic biosequence transformers for modeling protein–nucleic acid interactions
| Year | Share index |
|---|---|
| 2022 | 1026.5 |
| 2023 | 1052.9 |
| 2024 | 1295.2 |
| 2025 | 960.2 |
Opportunities · 0414.8% of this theme group
Studies present emerging phytochemical agents and organ‑on‑chip systems for testing antimicrobial efficacy.
Antimicrobial (35) · Epitope (41) · Drug discovery (66) · Antibiotics (31)
Bioactive Phytochemicals in Experimental Models of Multiple Sclerosis: Mechanisms, Efficacy, and Translational Potential
Lymphatics-on-a-chip microphysiological system: engineering lymphatic structure and function <i>in vitro</i>
| Year | Share index |
|---|---|
| 2022 | 172.7 |
| 2023 | 170.1 |
| 2024 | 187.2 |
| 2025 | 238.5 |
Opportunities · 0514.4% of this theme group
Works highlight microRNA and stochastic modeling approaches to improve cancer diagnosis and therapy prediction.
Cancer (250) · Breast cancer (94) · Immunotherapy (80) · Colorectal cancer (48)
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer
Advancing Cancer Research Through Stochastic Modeling: Insights into Tumor Growth, Evolution, and Treatment Response
| Year | Share index |
|---|---|
| 2022 | 2471.1 |
| 2023 | 3143.1 |
| 2024 | 2665.0 |
| 2025 | 2400.0 |
Opportunities · 0611.1% of this theme group
Papers discuss multiplexed CRISPR strategies and RNA‑editing tools for precise disease‑targeted interventions.
CRISPR (114) · Genome editing (66) · Cas9 (43) · Gene (125)
Multiplex Genome Engineering Using CRISPR/Cas Systems
RNA editing with CRISPR-Cas13
| Year | Share index |
|---|---|
| 2022 | 64.2 |
| 2023 | 65.9 |
| 2024 | 68.9 |
| 2025 | 71.3 |
Opportunities · 078.1% of this theme group
Research emphasizes reconstructing cellular states from spatial gene‑expression data to guide disease modeling.
Transcriptome (345) · Transcription factor (65) · Gene (125) · Gene expression (46)
Reconstructing biologically coherent cellular profiles from imaging-based spatial transcriptomics
Transcriptomic Correlation Identifies Cell Model Representatives for <i>MYCN</i> -Amplified Pediatric Neuroblastoma, Downstream Impact of Mo
| Year | Share index |
|---|---|
| 2022 | 2513.0 |
| 2023 | 2576.9 |
| 2024 | 2329.1 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 38.4% | 26.5% |
| Promising | 26.6% | 37.2% |
| Descriptive | 17.0% | 17.1% |
| Problem-identifying | 10.4% | 9.6% |
| Cautionary | 4.0% | 4.6% |
| Comparative | 2.0% | 3.9% |
| Critical | 1.7% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 39 | 0.32% | 2 (5.1%) | 0.28% |
| Bias & fairnessRNA-Based Biomarkers for Diagnostic Discrimination of Ischemic and Hemorrhagic Stroke: A Systematic Review | 4 | 0.03% | 1 (25.0%) | 0.04% |
| Safety & misuseLevels of Analysis in Evolutionary Genetics: Novel Genes and the Misuse of Homology | 2 | 0.02% | 1 (50.0%) | 0.01% |
| Energy & datacenter footprintMEGA12: Molecular Evolutionary Genetic Analysis Version 12 for Adaptive and Green Computing | 1 | 0.01% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Hardware, e-waste & supply chain | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Company counts, hiring and disclosed funding across the recorded hubs.
28.5% across the displayed hubs
7 companies hiring · $877.1M disclosed funding
Explore companies in San Francisco ↗17.6% across the displayed hubs
5 companies hiring · $649.1M disclosed funding
Explore companies in New York City ↗
13.3% across the displayed hubs
4 companies hiring · $682.0M disclosed funding
Explore companies in Boston ↗
9.4% across the displayed hubs
4 companies hiring · $253.6M disclosed funding
Explore companies in Cambridge ↗
9.0% across the displayed hubs
4 companies hiring · $369.9M disclosed funding
Explore companies in Austin ↗7.8% across the displayed hubs
4 companies hiring · $90.2M disclosed funding
Explore companies in San Diego ↗
7.4% across the displayed hubs
1 companies hiring · $19.4M disclosed funding
Explore companies in Philadelphia ↗
7.0% across the displayed hubs
2 companies hiring · $27.5M disclosed funding
Explore companies in Raleigh ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗